Abstract
ABSTRACTIntroduction: Anaplastic thyroid cancer (ATC) is one of the most aggressive human malignancies (representing 15–40% of fatal TC cases), classified as stage IV by the American Joint Committee on Cancer, regardless of tumor size or presence of lymph node and distant metastases. A large number of genetic alterations are associated with ATC, especially causing dysfunctions in the ERK1/2-MEK1/2 and PI3K-AKT signaling pathways (BRAF, p53, RAS, EGFR, VEGFR1, VEGFR2, chromosomal rearrangements, etc). New drugs targeting these molecular pathways have recently been evaluated in ATC.Areas covered: This article reviews the recent advances in precision medicine for the treatment of ATC.Expert commentary: Interesting results have been reported with molecules targeting different pathways: 1) BRAF (dabrafenib/trametinib, vemurafenib); 2) angiogenesis (sorafenib, combretastatin, vandetanib, sunitinib, lenvatinib, CLM3, etc); 3) EGFR (gefitinib); 4) PPARγ agonists (rosiglitazone, pioglitazone, efatutazone).The potentiality of targeted drugs to synergize with radiation, chemotherapy, or other targeted drugs is currently under investigation to bypass resistance to a single drug. New affordable individual genomic analyses as well as the possibility to test these new treatments in primary cells from each ATC patient in vitro, could allow the personalization of the therapy, increasing the therapeutic effectiveness and avoiding the use of ineffective drugs.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Expert Review of Precision Medicine and Drug Development
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.